|Healthcare: Pricing & Reimbursement-Highly Recommended|
|Healthcare: Pricing & Reimbursement-Recommended|
|Arnold & Porter Kaye Scholer|
|Covington & Burling|
|Morgan Lewis & Bockius|
|Licensing & Collaboration-Highly Recommended|
|Covington & Burling|
|Latham & Watkins|
|Morgan Lewis & Bockius|
|Ropes & Gray|
|Wilson Sonsini Goodrich & Rosati|
|Licensing & Collaboration-Recommended|
|Fenwick & West|
|McDermott Will & Emery|
|Mintz Levin Cohn Ferris Glovsky & Popeo|
|Morrison & Foerster|
|Wiggin and Dana|
Finance & Transactional
Reed Smith is a full-service firm widely known for exceptional practices relating to licensing and collaboration agreements, regulatory counsel in the area of pricing and reimbursement, and all facets of litigation. Reed Smith is one of several firms with a wealth of contacts in government. The firm's standout corporate law practitioner is Princeton-based, Diane Frenier, whose specialties include securing research and licensing agreements for mid-sized pharmaceutical and biotechnology companies. Frenier's skill set includes familiarity with mergers and divestments, equity financing and securities, capital markets activities and collaborative agreements.
Also based out of Princeton, Betty Yan has committed her time in recent months to representing GlaxoSmithKline in the divestment of Treximet to Pernix Therapeutics, which required renegotiating contract terms with suppliers, licensors, and royalty companies. Yan has represented GSK with two separate $500 million divestments to Biovail, as well as other GSK divestments to Apotex and KRIM Biopharma.
Clients appreciate the firm's "depth of expertise in the industry as a whole" and cite attorneys' abilities to provide advice concerning regulatory issues of paramount importance. Further, clients identify the firm's expertise concerning the FCPA and UK Bribery Act as particularly valuable.
A full-service firm with exceptional capabilities in the liability area, Reed Smith maintains a strong roster of specialists including Barbara Binis, Michael Scott and Michael Brown. The firm's work on behalf of American Medical Systems in surgical mesh litigation prompted one industry competitor to say of Binis, "she has been doing a terrific job coordinating and handling MDLs for AMS and is doing a really impressive strategic job," adding, "she is someone to keep on the radar as a noteworthy practitioner in her area." Binis leads Reed Smith's Endo team, serving as national counsel to the company and its subsidiary AMS in the In re Transvaginal Mesh Litigation. Reed Smith is responsible for overall defense strategy, lead trial counsel roles and overall coordination in this mass tort litigation involving 11 surgical mesh products that treat pelvic organ prolapse and stress urinary incontinence. More than 26,000 cases have been filed, and in 2012, Binis settled an inventory of cases for the client on extremely favorable grounds, the first settlement of its kind among all the pelvic mesh manufacturers. Endo has agreed to pay $830 million to settle a substantial majority of the vaginal mesh lawsuits. Of the 26,000 pending claims, agreements in principle have been reached with several plaintiffs' firms to resolve some 20,000 claims.
Brown is a frequent mention in conversations with competitors, with the suggestion offered that "his work in the device space for Medtronic, particularly with respect to preemption issues, has been top tier." Brown, as co-counsel to Pepper Hamilton and Mayer Brown, defends the company in all aspects of the INFUSE Bone Graft litigation pending across the country. The allegations claim that a bone morphogenetic protein device designed to grow bone and assist spinal fusion is defective and that Medtronic illegally promoted the product for an off label use. The first INFUSE trial in the country began in 2014 in Los Angeles, and there are nearly 1,000 cases pending nationwide.
Reed Smith is a Washington DC-based firm with an expanding life sciences practice that offers services in fraud and abuse, pricing and reimbursement, and product liability. The firm assists companies with commercialization strategies and represents a spectrum of clients – from hospitals and nursing homes, to wholesalers, distributors, and manufacturers. One peer notes that the firm is "very strong in pricing and reimbursement" issues. Joseph Metro is the firm's expert in residence on the 340B drug program and is also active in consignment modeling and distribution agreements for biosimilar products. He was recently involved in a settlement with the Office of Inspector General regarding late reporting of pricing data to the Center for Medicare & Medicaid Services and Medicaid Rebate Program. Additionally, he managed to get a false claims case dismissed for a drug manufacturer regarding reporting and classification of pre-62 drugs. 2016 LMG Life Sciences Star Robert Hill, although fundamentally a corporate lawyer dealing with commercial contracts, has a deep understanding of regulatory issues and basic sales and distribution. Carol Loepere and Scot Hasselman focus their practices on fraud, abuse, and transactional work. Loepere serves as lead attorney in giving outside general counsel to the American Health Care Association, the national trade association of 11,000 nursing facilities, assisted living residences and other post-acute care providers. Hasselman is involved as national counsel representing Life Care Centers of America in a high-profile False Claims Act case related to its rehabilitation services.